A Review of Clinical Trials Assessing the Efficacy and Safety of Newer Antiarrhythmic Drugs in Atrial Fibrillation

Gerald Naccarelli, Deborah Wolbrette, Luna Bhatta, Mazhar Khan, John Hynes, Soraya Samii, Jerry Luck

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Clinical trials assessing the efficacy of antiarrhythmic drugs for terminating atrial fibrillation have demonstrated that rate control drugs have little to no added efficacy compared to placebo; however, spontaneous conversion of recent-onset atrial fibrillation is common. Antiarrhythmic drugs such as oral dofetilide, oral bolus-flecainide and propafenone and intravenous ibutilide all have a role in terminating atrial fibrillation. Active comparator trials have demonstrated that amiodarone is more efficacious in maintaining sinus rhythm than propafenone and sotalol. Multiple trials have demonstrated the safety of amiodarone, sotalol, dofetilide and azimilide in a post-myocardial infarction population and amiodarone and dofetilide in a congestive heart failure population. Newer antiarrhythmic agents, some with novel mechanisms of action, will add to the pharmacologic armamentarium in treating atrial fibrillation.

Original languageEnglish (US)
Pages (from-to)215-222
Number of pages8
JournalJournal of Interventional Cardiac Electrophysiology
Volume9
Issue number2
DOIs
StatePublished - Oct 2003

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'A Review of Clinical Trials Assessing the Efficacy and Safety of Newer Antiarrhythmic Drugs in Atrial Fibrillation'. Together they form a unique fingerprint.

Cite this